Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel

Clinical Nutrition ESPEN
Samantha J CushenAoife M Ryan

Abstract

Body composition may influence clinical outcomes of certain chemotherapeutic agents. We examined the prognostic significance of skeletal muscle mass and adipose tissue on docetaxel toxicity and overall survival in patients with metastatic castrate resistant prostate cancer (mCRPC). A retrospective review of patients medical records with mCRPC, treated with docetaxel was conducted. Body composition parameters (skeletal muscle mass, muscle attenuation [MA], visceral and subcutaneous adipose tissue) were measured at L3 by computed tomography (CT) and defined using previously established cut points. Toxicity profile was assessed after 3 cycles of the drug and graded according to the National Cancer Institute Common Toxicity Criteria (version 4). Overall survival was analysed. Overall 63 patients, mean age 69 years (SD 8.3), were included. Sarcopenia was present in 47% (n = 30) and of these 26.7% (8/30) were sarcopenic obese. Common toxicities (all grades) observed included fatigue (80.9%), pain (46%), and constipation (34.9%). DLT occurred in 22 (34.9%) patients; of these 10 patients (15.8%) experienced dose reductions and 12 patients (19%) experienced dose terminations. Measurements of adiposity were not predictive of DLT, however...Continue Reading

Citations

Mar 15, 2018·Current Opinion in Urology·Tyler Sheetz, Cheryl T Lee
Sep 21, 2017·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Manrique Pascual-GelerMaria Jesus Alvarez-Cubero
Mar 21, 2020·Clinical Physiology and Functional Imaging·Taiara Scopel PoltronieriGabriela Villaça Chaves
Apr 19, 2020·Japanese Journal of Clinical Oncology·Takashi IkedaKazunari Tanabe
Jun 8, 2018·Cancer Chemotherapy and Pharmacology·Jessica J Hopkins, Michael B Sawyer
Nov 21, 2019·Prostate Cancer and Prostatic Diseases·Judith Stangl-KremserPascal Baltzer
Oct 3, 2019·Archives of Endocrinology and Metabolism·Erica Roberta BarbalhoAna Paula Trussardi Fayh
Oct 8, 2020·Arquivos De Gastroenterologia·Ana Paula Noronha BarrÈreNelson Hamerschlak
Jan 15, 2021·Nature Reviews. Urology·Ilona Csizmadi, William J Aronson
Dec 27, 2019·Critical Reviews in Oncology/hematology·G F P AleixoG R Williams
Feb 1, 2021·Cancer Treatment and Research Communications·Adriana M ColettaNeeraj Agarwal
Dec 7, 2018·Pharmacology & Therapeutics·Marc HilmiFrançois Goldwasser
May 10, 2021·Current Opinion in Urology·Victoria JahrreissShahrokh F Shariat
Aug 31, 2021·JAMA Network Open·Christina A FlemingHenry P Redmond
Jul 7, 2021·Prostate Cancer and Prostatic Diseases·Alberto MartiniMatthew D Galsky
Nov 10, 2021·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Taiara Scopel PoltronieriGabriela Villaça Chaves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.